Member Info for ontarget

By comparing market cap but then also dividing by the number of shares in issue you are accounting for the dilution twice over. The market cap already naturally takes into account the number of shares in issue.

I think enterprise value is the most objective measure.

2013: £34m market cap - £8m net cash = £26m

2023: £7m market cap - £1m net cash = £6m

So the market is currently valuing the company (after taking into account cash/debt) at less than 1/4 of what it did in 2013.

Not much cash here but fully funded until end of 2024 with partner-funded phase 2/3 trial coming up. A bit like EVG except they have a bit more cash and a bit more going on. Holding both.

82m shares in issue in 2013 compared to 416m now, so a factor of 5.

https://www.lse.co.uk/rns/IMM/additional-listing-3a9w8hj7rb8yxa3.html

Already there on the monthly, and weekly assuming today holds above $2038.

Who is it that is stipulating that gold in the ground is worth

So is the shareprice if you factor in inflation.

The first link is more interesting imo given it's talking about Firefly's BNA platform being used in the upcoming STP1 and STP2 (SFX-01) phase 2 trials, which could suggest further refinement of phenotype subgroups within the patient group already identified by DEPI. It's clearly going to be an interesting and perhaps complex trial.

It will be Stalicla applying for the IND, but yes I would assume the full report of the Phase1b was a significant part of the information needed for the application. The proposed design of the trial will be another major part which as of the 31/10 full year report was still being thrashed out.

· Discussions continue with partner Stalicla SA on optimal design of the Phase 2 study in autism spectrum disorder.

The good news is based on other companies experiences the FDA appear to be moving quite quickly these days so once the application is in things should move at a good pace. Better to get it right first time as well than rush it and get a clinical hold.

Not sure what point you’re trying to make DSFLAT?

One thing i am sure about is the timelines including when the IND application is filed with the FDA are under the control of Stalicla, and Evgen directors are unlikely to have come up with them themselves off the top of their heads?

Seems more likely to be next week.

And weirdly the board moderator seems to be encouraging it, bizarre.

One interesting thing in today is the very high grade intervals at Ramula which Eric alluded to in the recent Q&A. Yes not hugely wide but on the other hand generally shallow and the first time we've seen such grades from Ramula I believe.

£100,000 nominal divided by the nominal value 0.01p gives you the number of shares being authorised (1 billion)

Oops H1 2025

H1 2024

But it's absolutely ginormous compared to your £400 punt Kingalf

In the last 12 months they have done 4 InvestorMeet presentationa/q&a's which is a big improvement to previous years (when they did virtually no presentations/promotion).

But yes still plenty of room for improvement.

Agree it's hard to know who the intended audience is. I would guess this is the sort of magazine that pharma companies might put in their canteen for employees to read on their lunchbreak.

Didn't you used to be a holder here?

As you know they are focusing on the pharmaceutical applications (agreement with Juvenescence for the neutraceutical side was ended earlier this year), of which the foremost are oncology and neurological disorders - clinical trials for both of these areas are anticipated in the next months. Licence deal with Stalicla for the latter.

Do you seriously not know what enterprise value means BushyTail?